doi: 10.1016/S2214-109X(21)00593-3.
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
Affiliations
- PMID: 35180408
- PMCID: PMC8846615
- DOI: 10.1016/S2214-109X(21)00593-3
Item in Clipboard
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
Lancet Glob Health.
2022 Mar.
No abstract available
Conflict of interest statement
The authors acknowledge the contributions of all members of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization and the SAGE Working Group on COVID-19 Vaccines. EPKP is a consultant for the SAGE Working Group on COVID-19 vaccines. SD, MM, KLO’B, JH, and AW-S are staff of WHO. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. SK and HN are members of SAGE. DCK is a member of the SAGE Working Group on COVID-19 vaccines.
Figures
Antibody response rate following an additional COVID-19 vaccine dose in people who are immunocompromised (A) Cumulative antibody response rates before and after an additional dose in different patient subgroups across 13 studies with paired data. Lines link estimates from individual study populations. The same participants were measured before and after the additional dose. (B) Antibody response rates following an additional dose among patients with low or no detectable antibodies after the standard primary series (19 estimates from 17 studies). Note that antibody response criteria and patient characteristics varied among studies, restricting comparability (see appendix pp 3–5 for details). Estimates for subgroups receiving mRNA and vectored vaccines were extracted separately where possible. *Denominator includes patients who did not receive an additional dose but responded after the primary vaccine series. †Post-vaccination data available for a subset of the cohort.
